Alliance Global raised the firm’s price target on Verastem (VSTM) to $18 from $16 and keeps a Buy rating on the shares after the company’s Q1 earnings report included detailing the progress made on the launch of AVMAPKI and FAKZYNJA co-pack for KRAS mutant recurrent low-grade serous ovarian cancer.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem reports Q1 adjusted EPS (43c), consensus (47c)
- Verastem Updates Strategy for RAS/MAPK Oncology Pipeline
- VSTM Upcoming Earnings Report: What to Expect?
- Verastem announces launch of Reimagine Recurrent LGSOC campaign
- Buy Rating on Verastem: Favorable Risk‑Reward for VS‑7375 Driven by Superior Early Efficacy vs. Zoldonrasib and Improving Safety Outlook